Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 2:43 AM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Torsgatan 11

Stockholm,  111 23

Sweden

Founded in 2005

97 Employees

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Founder, Chief Executive Officer, President and Director
Age: 41
Chief Financial Officer
Age: 44
Head of development and Quality Assurance
Director of Bluefish India office
Compensation as of Fiscal Year 2015.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Company Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Earnings Guidance for the Fourth Quarter and Full Year of 2015

Bluefish Pharmaceuticals AB reported consolidated and parent company unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the consolidated company reported net sales of SEK 74.208 million against SEK 44.671 million a year ago. Operating loss was SEK 3.464 million against SEK 13.027 million a year ago. Loss after financial items was SEK 4.594 million against SEK 14.430 million a year ago. Loss for the period was SEK 4.778 million against SEK 15.133 million a year ago. Loss per basic and diluted share was SEK 0.06 against SEK 0.19 a year ago. Cash flow from operating activities was SEK 24.337 million against cash flow used in operating activities of SEK 16.302 million a year ago. EBITDA was SEK 6.464 million against LBITDA of SEK 6.932 million a year ago. Investments in intangible assets were SEK 3.2 million against SEK 3.1 million a year ago. For the nine months, the consolidated company reported net sales of SEK 210.870 million against SEK 127.477 million a year ago. Growth was fueled by the strong sales performance in Spain. Operating loss was SEK 13.457 million against SEK 49.658 million a year ago. Loss after financial items was SEK 16.304 million against SEK 53.809 million a year ago. Loss for the period was SEK 17.369 million against SEK 54.873 million a year ago. Loss per basic and diluted was SEK 0.21 against SEK 0.73 a year ago. Cash flow from operating activities was SEK 27.447 million against cash flow used in operating activities of SEK 34.625 million a year ago. EBITDA was SEK 9.192 million against LBITDA of SEK 32.663 million a year ago. The substantially improved cash flow from operating activities is also an effect of the positive sales growth and improved profitability during the period. Investments in intangible assets were SEK 12.2 million against SEK 11 million a year ago. Investments in property, plant and equipment amounted was SEK 4.8 million against SEK 3.9 million, consisted primarily of laboratory equipment for the company’s development and analysis activities. Equity per share was SEK 1.04. For the quarter, the parent company reported net sales of SEK 72.622 million against SEK 46.671 million a year ago. Operating loss was SEK 1.610 million against SEK 9.871 million a year ago. Net loss for the period was SEK 3.251 million against SEK 12.066 million a year ago. For the nine months, the parent company reported net sales of SEK 204.652 million against SEK 127.889 million a year ago. Operating loss was SEK 10.330 million against SEK 46.770 million a year ago. Net loss for the period was SEK 15.219 million against SEK 53.175 million a year ago. The company expects a slightly lower gross margin in the fourth quarter compared to the previous quarters of 2015. The company expects that sales in the last quarter of the year will be below the level achieved in the third quarter, but that there will still be growth as compared to the same period last year. For the full year of 2015, gross margin is expected to exceed the level achieved last year, fluctuation in net sales and earnings between quarters and positive EBITDA.

Bluefish Pharmaceuticals AB Announces Unaudited Consolidated and Parent Company Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Bluefish Pharmaceuticals AB announced unaudited consolidated and parent company earnings results for the second quarter and six months ended June 30, 2015. For the quarter, on consolidated basis, the company announced net sales of SEK 65,880,000 compared to SEK 38,316,000 for the same period a year ago. Operating loss was SEK 6,498,000 compared to SEK 21,362,000 for the same period a year ago. Loss after financial items was SEK 7,607,000 compared to SEK 22,762,000 for the same period a year ago. Loss for the period was SEK 7,988,000 compared to SEK 22,928,000 for the same period a year ago. Basic and diluted loss per share was SEK 0.10 compared to SEK 0.32 for the same period a year ago. LBITDA was SEK 925,000 compared to SEK 15,044,000 for the same period a year ago. Cash outflow from operating activities was SEK 5,684,000 compared to cash inflow from operating activities of SEK 220,000 for the same period a year ago. For the six months, on consolidated basis, the company announced net sales of SEK 136,662,000 compared to SEK 82,806,000 for the same period a year ago. Operating loss was SEK 9,993,000 compared to SEK 36,631,000 for the same period a year ago. Loss after financial items was SEK 11,710,000 compared to SEK 39,379,000 for the same period a year ago. Loss for the period was SEK 12,591,000 compared to SEK 39,740,000 for the same period a year ago. Basic and diluted loss per share was SEK 0.16 compared to SEK 0.55 for the same period a year ago. EBITDA was SEK 2,728,000 compared to LBITDA of SEK 25,731,000 for the same period a year ago. Cash outflow from operating activities was SEK 3,111,000 compared to cash inflow from operating activities of SEK 18,324,000 for the same period a year ago. For the quarter, on parent company basis, the company announced net sales of SEK 63,234,000 compared to SEK 37,256,000 for the same period a year ago. Operating loss was SEK 6,164,000 compared to SEK 21,936,000 for the same period a year ago. Net loss for the period was SEK 8,117,000 compared to SEK 23,954,000 for the same period a year ago. For the six months, on parent company basis, the company announced net sales of SEK 132,030,000 compared to SEK 81,218,000 for the same period a year ago. Operating loss was SEK 8,720,000 compared to SEK 36,899,000 for the same period a year ago. Net loss for the period was SEK 11,968,000 compared to SEK 41,109,000 for the same period a year ago.

Bluefish Pharmaceuticals AB to Report Nine Months, 2015 Results on Nov 19, 2015

Bluefish Pharmaceuticals AB announced that they will report nine months, 2015 results on Nov 19, 2015

Similar Private Companies By Industry

Company Name Region
Recip AB Europe
B&E Participation AB Europe
Biosynth Svenska AB Europe
Natumin Pharma ASA Europe
Niconovum AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.